Heterotopic Ossification Mechanisms and Management

Heterotopic ossification (HO) refers to the pathological formation of mature bone in soft tissues, most frequently following trauma, surgery or neurological injury, but also arising in rare genetic conditions such as fibrodysplasia ossificans progressiva (FOP). The process typically involves an aberrant inflammatory cascade that establishes a niche rich in cytokines and growth factors, recruiting mesenchymal progenitor cells. These progenitors undergo endochondral ossification, recapitulating developmental bone formation through cartilage intermediates and driven by signalling axes including bone morphogenetic proteins (BMPs), transforming growth factor-β (TGF-β), activin A and hedgehog pathways. Mechanical factors, extracellular matrix stiffening and immune cell phenotypes further modulate osteogenic differentiation. Current management encompasses prophylactic measures with non-steroidal anti-inflammatory drugs and radiotherapy, surgical excision of mature lesions and emerging targeted strategies such as receptor-blocking antibodies, small-molecule inhibitors and biomaterial-based delivery systems designed to interrupt key signals or restore tissue homeostasis.

Research from Nature Portfolio

Recent clinical investigations of an activin A-blocking antibody in adults with FOP demonstrated effective suppression of new ectopic bone lesions during open-label treatment, indicating that ligand neutralisation can arrest progressive soft tissue ossification with an acceptable safety profile. Parallel genetic studies have uncovered a structural variant that disrupts a topologically associating domain, causing enhancer hijacking at the ARHGAP36 locus. Misexpression of ARHGAP36 in fibroblasts was shown to inhibit TGF-β signalling, activate hedgehog effectors and upregulate extracellular matrix components, thereby delineating a novel gene network contributing to heterotopic bone formation and offering a candidate target for future gene-based therapies.

Heterotopic Ossification Mechanisms and Management publication trend

The graph below shows the total number of articles in heterotopic ossification mechanisms and management across all publications each year (not limited to Nature Index journals).

Technical terms

Heterotopic ossification: Formation of bone tissue outside the skeletal system in muscle or connective tissues.

Endochondral ossification: Process by which cartilage is gradually replaced by bone during development or pathological bone formation.

Activin A: A growth factor of the transforming growth factor-β superfamily that regulates inflammation and mesenchymal cell osteogenic differentiation.

Apoptotic vesicle: Membrane-bound particles released from apoptotic cells that can mediate intercellular signalling and matrix remodelling.

scRNA-seq: Single-cell RNA sequencing, a technique for profiling transcriptomes at the individual cell level to resolve cellular heterogeneity.

Hydrogel: A water-swollen, crosslinked polymer network used for controlled release of therapeutics and modification of tissue microenvironments.

References

1. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine (2023).
2. Enhancer hijacking at the ARHGAP36 locus is associated with connective tissue to bone transformation. Nature Communications (2023).
3. Tppp3+ synovial/tendon sheath progenitor cells contribute to heterotopic bone after trauma. Bone Research (2023).
4. Calcified apoptotic vesicles from PROCR+ fibroblasts initiate heterotopic ossification. Journal of Extracellular Vesicles (2024).
5. Inflammation‐Responsive Hydrogel Spray for Synergistic Prevention of Traumatic Heterotopic Ossification via Dual‐Homeostatic Modulation Strategy. Advanced Science (2023).
6. Heterotopic Ossification: A Comprehensive Review. JBMR Plus (2019).